Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company focused on developing treatments for serious metabolic diseases, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The presentation is scheduled for Wednesday, September 4, 2024, at 7:45 a.m. E.T. in New York, NY.
Investors and interested parties can access a live webcast of the presentation through the investor relations section of Akero's website at www.akerotx.com. For those unable to attend the live event, an archived replay will be made available on the company's website following the presentation.
Akero Therapeutics, Inc. (Nasdaq: AKRO), una società in fase clinica focalizzata nello sviluppo di trattamenti per gravi malattie metaboliche, ha annunciato la sua partecipazione alla 22ª Conferenza Annuale Globale sulla Salute di Morgan Stanley. La presentazione è programmata per mercoledì 4 settembre 2024, alle 7:45 a.m. E.T. a New York, NY.
Investitori e parti interessate possono accedere a un webcast in diretta della presentazione attraverso la sezione delle relazioni con gli investitori del sito web di Akero all'indirizzo www.akerotx.com. Per coloro che non possono assistere all'evento dal vivo, sarà disponibile un replay archiviato sul sito web dell'azienda dopo la presentazione.
Akero Therapeutics, Inc. (Nasdaq: AKRO), una empresa en etapa clínica centrada en el desarrollo de tratamientos para enfermedades metabólicas graves, ha anunciado su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley. La presentación está programada para el miércoles 4 de septiembre de 2024, a las 7:45 a.m. E.T. en Nueva York, NY.
Los inversores y partes interesadas pueden acceder a un webcast en vivo de la presentación a través de la sección de relaciones con inversores del sitio web de Akero en www.akerotx.com. Para aquellos que no puedan asistir al evento en vivo, se dispondrá de un retransmisión archivada en el sitio web de la empresa después de la presentación.
Akero Therapeutics, Inc. (Nasdaq: AKRO), 심각한 대사 질환 치료제 개발에 주력하는 임상 단계 기업이 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 발표는 2024년 9월 4일 수요일, 오전 7:45 E.T.에 뉴욕에서 예정되어 있습니다.
투자자 및 이해 관계자는 Akero의 웹사이트(www.akerotx.com) 투자자 관계 섹션을 통해 발표의 실시간 웹캐스트를 이용할 수 있습니다. 실시간 이벤트에 참석할 수 없는 분들을 위해 발표 후 회사 웹사이트에 아카이브 재생이 제공될 예정입니다.
Akero Therapeutics, Inc. (Nasdaq: AKRO), une entreprise en phase clinique axée sur le développement de traitements pour des maladies métaboliques graves, a annoncé sa participation à la 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley. La présentation est prévue pour le mercredi 4 septembre 2024, à 7h45 E.T. à New York, NY.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section relations investisseurs du site Web d'Akero à l'adresse www.akerotx.com. Pour ceux qui ne peuvent pas assister à l'événement en direct, une rediffusion archivée sera disponible sur le site de l'entreprise après la présentation.
Akero Therapeutics, Inc. (Nasdaq: AKRO), ein Unternehmen in klinischer Phase, das sich auf die Entwicklung von Behandlungen für schwere metabolische Erkrankungen konzentriert, hat seine Teilnahme an der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley bekannt gegeben. Die Präsentation ist für Mittwoch, den 4. September 2024, um 7:45 Uhr E.T. in New York, NY, angesetzt.
Investoren und Interessierte können über den Bereich Investor Relations auf der Website von Akero unter www.akerotx.com auf ein Live-Webcast der Präsentation zugreifen. Für diejenigen, die an der Live-Veranstaltung nicht teilnehmen können, wird eine archivierte Wiederholung nach der Präsentation auf der Unternehmenswebsite zur Verfügung gestellt.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, at 7:45 a.m. E.T. in New York, NY.
A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH or compensated cirrhosis due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
Media Contact:
Peg Rusconi
617.910.6217
peg.rusconi@deerfieldgroup.com
FAQ
When is Akero Therapeutics (AKRO) presenting at the Morgan Stanley Healthcare Conference?
How can I watch Akero Therapeutics' (AKRO) presentation at the Morgan Stanley conference?
What type of company is Akero Therapeutics (AKRO)?
Where is the Morgan Stanley Healthcare Conference being held in 2024?
